Filtros de búsqueda

Lista de obras de Carolyn F. Deacon

A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes

artículo científico publicado en 2016

A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients

artículo científico publicado en 2018

A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.

artículo científico publicado en 2018

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite

artículo científico publicado en 2017

Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow

article

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects

Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice

Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones

artículo científico publicado en 2011

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

artículo científico publicado en 2016

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes

scientific article published on April 2008

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

artículo científico publicado en 2011

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas.

artículo científico publicado en 2018

Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test

artículo científico publicado en 2010

Cephalic phase secretion of insulin and other enteropancreatic hormones in humans

artículo científico publicado en 2015

Cerebral effects of GLP-1 receptor blockade before and after Roux-en-Y Gastric Bypass in obese women: a proof-of-concept resting-state fMRI study

artículo científico publicado en 2020

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

artículo científico publicado en 2013

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production

artículo científico publicado en 2017

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

artículo científico publicado en 2015

Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia

artículo científico publicado en 2016

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.

artículo científico publicado en 2008

Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men.

artículo científico publicado en 2016

Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men.

artículo científico publicado en 2009

Differential regional metabolism of glucagon in anesthetized pigs

artículo científico publicado en 2003

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes

artículo científico publicado en 2007

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

scientific article published on 14 September 2020

Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective

artículo científico publicado en 2002

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

artículo científico publicado en 2005

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

scientific article published on 21 May 2011

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

artículo científico publicado en 2010

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

artículo científico publicado en 2013

Dissociated incretin hormone response to protein versus fat ingestion in obese subjects

article

Do we know the true mechanism of action of the DPP-4 inhibitors?

artículo científico publicado en 2017

Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes.

artículo científico publicado en 2016

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

artículo científico publicado en 2014

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

article

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

artículo científico publicado en 2011

Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study

artículo científico publicado en 2018

Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males

artículo científico publicado en 2014

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

artículo científico publicado en 2011

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.

artículo científico publicado en 2011

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

artículo científico publicado en 2013

Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?

artículo científico publicado en 2014

Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin

artículo científico publicado en 2014

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes

artículo científico publicado en 2014

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

artículo científico publicado en 2007

Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues

artículo científico publicado en 2017

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

artículo científico publicado en 2015

Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats

artículo científico publicado en 2007

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

artículo científico publicado en 2016

Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.

artículo científico publicado en 2017

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

artículo científico publicado en 2011

GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations

artículo científico publicado en 2006

GLP-1 Is a Coronary Artery Vasodilator in Humans

artículo científico publicado en 2018

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

artículo científico publicado en 2003

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

artículo científico publicado en 2011

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

artículo científico publicado en 2002

Ghrelin secretion in humans - a role for the vagus nerve?

artículo científico publicado en 2018

Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes

artículo científico publicado en 2016

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

artículo científico publicado en 2004

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

artículo científico publicado en 2008

Glucagon-like peptide-1, glucose homeostasis and diabetes

scientific article published on 18 March 2008

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

artículo científico publicado en 1999

Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans

artículo científico publicado en 2020

Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice

artículo científico publicado en 2006

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

artículo científico publicado en 2014

Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans

artículo científico publicado en 2009

Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men

artículo científico publicado en 2018

Immunoassays for the incretin hormones GIP and GLP-1.

artículo científico publicado en 2009

Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans

artículo científico publicado en 2010

Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals

artículo científico publicado en 2012

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

artículo científico publicado en 2003

Important species differences regarding lymph contribution to gut hormone responses

artículo científico publicado en 2015

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.

artículo científico publicado en 2015

Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

artículo científico publicado en 2008

Incretin effect after oral amino acid ingestion in humans.

artículo científico publicado en 2014

Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans

artículo científico publicado en 2011

Incretin hormone secretion over the day.

scientific article published on January 2010

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

artículo científico publicado en 2007

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

artículo científico publicado en 2006

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

article

Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats.

artículo científico publicado en 2009

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

artículo científico publicado en 2004

Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

artículo científico publicado en 2012

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

artículo científico publicado en 2018

Is there a place for incretin therapies in obesity and prediabetes?

artículo científico publicado en 2013

Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?

artículo científico publicado en 2012

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

artículo científico publicado en 2008

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

artículo científico publicado en 2012

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

artículo científico publicado en 2010

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

artículo científico publicado en 2010

Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes

artículo científico publicado en 2011

MK-431 (Merck).

artículo científico publicado en 2005

Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.

artículo científico publicado en 2014

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

artículo científico publicado en 2007

Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV

artículo científico publicado en 2006

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.

artículo científico publicado en 2016

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.

artículo científico publicado en 2003

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

artículo científico publicado en 2005

Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs

artículo científico publicado en 2004

No Effect of Aprotinin (Trasylol) on Degradation of Exogenous and Endogenous Glucagon in Human, Mouse and Rat Plasma

No effects of a six-week intervention with glucagon-like peptide-1 receptor analogue on pancreatic volume and edema in obese men without diabetes

artículo científico publicado en 2020

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight

artículo científico publicado en 2005

Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans

artículo científico publicado en 2008

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

artículo científico publicado en 2016

Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes

artículo científico publicado en 2010

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation

artículo científico publicado en 2016

Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice

artículo científico publicado en 2019

Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

artículo científico publicado en 2018

Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells.

artículo científico publicado en 2016

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

artículo científico publicado en 2007

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

artículo científico publicado en 2007

Physiology of incretins in health and disease

artículo científico publicado en 2011

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake

artículo científico publicado en 2006

Potential cardiovascular effects of incretin-based therapies

artículo científico

Potential of liraglutide in the treatment of patients with type 2 diabetes.

artículo científico publicado en 2009

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

artículo científico publicado en 2009

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.

artículo científico publicado en 2016

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.

artículo científico publicado en 2014

Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery

artículo científico publicado en 2010

Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men

scientific article published on 10 May 2019

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

artículo científico publicado en 2009

Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.

artículo científico publicado en 2009

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

artículo científico publicado en 2010

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

artículo científico publicado en 2004

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

artículo científico publicado en 2005

Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.

artículo científico publicado en 2005

Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes

artículo científico publicado en 2016

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

artículo científico publicado en 2014

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies

artículo científico publicado en 2014

Stability of glucagon-like peptide 1 and glucagon in human plasma

artículo científico publicado en 2015

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

artículo científico publicado en 2004

Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

artículo científico publicado en 2013

The Use of Gastrostomy Tube for the Long-Term Remission of Hyperinsulinemic Hypoglycemia After Roux-en-y Gastric Bypass: A Case Report

The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial

article

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients

artículo científico publicado en 2007

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

artículo científico publicado en 2007

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose

artículo científico publicado en 2009

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

artículo científico publicado en 2008

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

artículo científico publicado en 2013

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study

artículo científico publicado en 2012

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

artículo científico publicado en 2006

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

artículo científico publicado en 2006

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

artículo científico publicado en 2010

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects

artículo científico publicado en 2014

The incretin system and its role in type 2 diabetes mellitus

artículo científico publicado en 2008

The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs

scientific article published on 01 July 2016

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

artículo científico publicado en 2002

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

artículo científico publicado en 2004

The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1.

artículo científico publicado en 2015

The structure of wheat bread influences the postprandial metabolic response in healthy men.

artículo científico publicado en 2015

Therapeutic strategies based on glucagon-like peptide 1.

artículo científico publicado en 2004

Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass

artículo científico publicado en 2003

What do we know about the secretion and degradation of incretin hormones?

artículo científico publicado en 2005

Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda